Kelainan Hemostasis pada pasien Covid-19
Abstrak
AbstractCoagulopathy in SARS-CoV-2 (Covid-19) patients is an emerge situation to treat because it
increases morbidity and mortality. Increased levels of tPA indicate spontaneous fibrinolysis as
well as a significant increase in Fibrin / Fibrinogen degradation product (FDP) and D-dimer
in Covid-19 patients. The invasion of the Covid-19 virus into the endothelial blood vessels
causes endothelial cell dysfunction, a decrease in the fibrinolytic function of the cells, which
predisposes to thrombus formation. In severe cases, IL-6 which is also released due to
endothelial damage predisposes to Sepsis-Induced Coagulopathy (SIC) and Disseminated
Intravascular Coagulation (DIC).
Keywords: SARS-CoV-2 (Covid-19), Coagulopathy, SIC, DIC.
Referensi
Seheult JN, Seshadri A, Neal MD. Fibrinolysis Shutdown and Thrombosis in Severe COVID-19.
J Am Coll Surg [Internet]. 2020;231(2):203–4. Available from:
https://doi.org/10.1016/j.jamcollsurg.2020.05.021
Eltayeb N, Abdulgader A, Hamza A, Hamza A, Awadelkareem H, Fadl O, et al. Venous
Thromboembolism in Covid-19 ICU Patients : A Narrative Review. 2020;3(July):35–43.
Umemura Y, Yamakawa K, Kiguchi T, Nishida T, Kawada M, Fujimi S. Hematological
Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced
Coagulopathy. J Clin Med. 2020;9(9):2875.
Gale AJ. åŸºå› çš„æ”¹å˜NIH Public Access. Bone. 2008;23(1):1–7.
Wolberg AS. NIH Public Access. 2013;114(2):275–85.
Kurniawan LB. Clinical Pathology and Majalah Patologi Klinik Indonesia dan Laboratorium
Medik. J Indones [Internet]. 2006;21(3):261–5. Available from:
http://journal.unair.ac.id/download-fullpapers-IJCPML-12-3-08.pdf
Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New Fundamentals in hemostasis. Physiol
Rev. 2013;93(1):327–58.
Masi P, Hékimian G, Lejeune M, Chommeloux J, Desnos C, Pineton De Chambrun M, et al.
Systemic inflammatory response syndrome is a major contributor to COVID-19-associated
coagulopathy: Insights from a prospective, single-center cohort study. Circulation.
;142(6):611–4.
Zuo Y. 済無No Title No Title. Sereal Untuk. 2018;51(1):51.
Ahmed S, Zimba O, Gasparyan AY. Thrombosis in Coronavirus disease 2019 (COVID-19)
through the prism of Virchow’s triad. Clin Rheumatol. 2020;39(9):2529–43.
Bronić A, Herak DC, Margetić S, Milić M. Croatian society of medical biochemistry and
laboratory medicine: National recommendations for blood collection, processing, performance
and reporting of results for coagulation screening assays prothrombin time, activated partial
thromboplastin time, thrombin time, fibrinogen and D-dimer. Biochem Medica. 2019;29(2):1–
Aggarwal M, Dass J, Mahapatra M. Hemostatic Abnormalities in COVID-19: An Update. Indian
J Hematol Blood Transfus [Internet]. 2020;36(4):616–26. Available from:
https://doi.org/10.1007/s12288-020-01328-2
Wright FL. Fibrinolytic shutdown correlation wuth thromboembolism. Ann Oncol.
;(January):19–20.
